8-K: Viatris Completes Divestiture of Over-the-Counter Business for Up to $1.95 Billion

Viatris has finalized the sale of its over-the-counter product business to Cooper Consumer Health for a total consideration of up to $1.95 billion.

Summary

• Viatris Inc. has completed the sale of its over-the-counter (OTC) business to Cooper Consumer Health.
• The transaction closed on July 3, 2024.
• The total consideration is up to $1.95 billion in cash on a cash-free, debt-free basis.
• Viatris received $1.85 billion in cash at closing, subject to adjustments for net indebtedness and working capital.
• An additional $100 million in contingent cash consideration is possible if Cooper Consumer Health's shareholders achieve a 2.5x return on their investment upon a change of control or IPO.
• Cooper Consumer Health also paid $25 million to Viatris as a partial advance for transition services.
• $120 million of the cash consideration was retained by the buyer pending the sale of certain portions of the business in select geographies.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a significant divestiture, which is generally positive. However, the contingent nature of some payments and the potential for adjustments temper the overall positive sentiment.

Positives

• Viatris has successfully completed the sale of its OTC business, generating significant cash proceeds.
• The transaction provides Viatris with up to $1.95 billion in cash, strengthening its financial position.
• The deal includes a potential for additional contingent cash consideration, offering further upside.

Negatives

• The final amount of cash received is subject to adjustments for net indebtedness and working capital.
• A portion of the cash consideration ($120 million) is being held back pending the sale of certain business portions.
• The contingent consideration of $100 million is not guaranteed and depends on the future performance of Cooper Consumer Health.

Risks

• The full $1.95 billion may not be realized due to potential adjustments and the contingent payment.
• There is a risk that the sale of certain portions of the business may not be completed, affecting the final consideration.
• The contingent consideration is dependent on a future change of control or IPO of the buyer's parent company, which is uncertain.
• There is a risk of goodwill or other impairment charges related to the transaction.

Future Outlook

The document includes forward-looking statements regarding the cash consideration payable to Viatris, which are subject to risks and uncertainties. The company does not commit to updating these statements.

Industry Context

This divestiture reflects a trend of pharmaceutical companies focusing on core business areas and divesting non-core assets. It allows Viatris to streamline its operations and potentially improve its financial position.

Comparison to Industry Standards

• Divestitures of non-core assets are common in the pharmaceutical industry as companies seek to optimize their portfolios.
• Comparable transactions include the sale of consumer health divisions by other large pharmaceutical companies, often to private equity firms or specialized consumer health companies.
• The valuation of this transaction, at up to $1.95 billion, is within the range of similar deals, though specific multiples would depend on the profitability and growth prospects of the divested business.

Stakeholder Impact

• Shareholders will likely view the transaction positively due to the cash infusion and potential for future gains.
• Employees in the divested business will transition to Cooper Consumer Health.
• Customers of the OTC products will now be served by Cooper Consumer Health.

Next Steps

• Viatris will likely focus on integrating the proceeds from the sale into its operations and strategic initiatives.
• The company may also need to manage the transition services agreement with Cooper Consumer Health.
• The sale of the remaining portions of the business in select geographies will need to be completed.

Key Dates

Keywords

divestiture, over-the-counter, OTC, acquisition, Viatris, Cooper Consumer Health, transaction, cash consideration, asset sale